永顺生物(839729) - 2023 Q3 - 季度财报

Financial Performance - Net profit attributable to shareholders for the first nine months of 2023 was CNY 57,737,233.37, down 2.71% from CNY 59,347,338.26 in the same period last year[10] - Operating income for the first nine months of 2023 was CNY 252,920,068.67, a slight decrease of 0.63% compared to CNY 254,511,982.81 in 2022[10] - Total operating revenue for the first nine months of 2023 was CNY 252,920,068.67, a decrease of 0.23% compared to CNY 254,511,982.81 in the same period of 2022[42] - Total profit for the first nine months of 2023 was CNY 65,58 million, a decrease of 3.16% from CNY 67.71 million in the previous year[46] - Operating profit for the first nine months of 2023 was CNY 61.41 million, down 8.73% from CNY 67.01 million in the previous year[46] - Basic and diluted earnings per share for the first nine months of 2023 were both CNY 0.21, compared to CNY 0.22 in the same period of 2022[45] - The basic earnings per share for the third quarter of 2023 was CNY 0.07, down 24.33% from CNY 0.09 in the same quarter of 2022[10] Assets and Liabilities - Total assets as of September 30, 2023, were CNY 842,554,434.81, a decrease of 3.03% compared to CNY 868,912,246.16 at the end of 2022[10] - The company's equity attributable to shareholders is ¥668,217,794.90, down from ¥696,141,073.57 at the end of 2022, representing a decrease of approximately 4.0%[36] - Total liabilities amounted to CNY 174,336,321.51, slightly up from CNY 172,771,034.88 in the previous period[40] - The company’s total liabilities to assets ratio remained stable at 20.69% for both the parent and consolidated entities[10] - The total current assets as of September 30, 2023, are ¥613,010,371.44, slightly down from ¥617,237,797.63 at the end of 2022[34] Cash Flow - The net cash flow from operating activities decreased by 68.54% to CNY 12,273,405.39, primarily due to increased procurement costs and tax payments[13] - The company reported a net cash flow from operating activities of CNY 12.27 million for the first nine months of 2023, significantly down from CNY 39.01 million in the same period of 2022[50] - Cash inflow from investment activities totaled CNY 84,103,841.08 in 2023, compared to CNY 50,781,702.97 in 2022, indicating an increase of about 65.7%[54] - Cash outflow for purchasing goods and services increased to CNY 85,038,695.87 in 2023 from CNY 67,582,957.19 in 2022, representing a rise of approximately 25.7%[53] - Total cash outflow from operating activities rose to CNY 202,799,976.13 in 2023, compared to CNY 178,686,546.59 in 2022, an increase of about 13.5%[53] Shareholder Activities - The company has been actively repurchasing shares, with a total of 360,000 shares repurchased by the end of the reporting period[12] - The company has initiated a share repurchase plan, approved on August 11, 2022, to enhance shareholder value[28] - As of July 20, 2023, the company has repurchased a total of 3,600,000 shares, accounting for 1.32% of the total share capital, with a total expenditure of ¥28,801,567.63, representing 66.92% of the planned repurchase fund limit[29] Other Income and Expenses - The company received government subsidies for technology renovation projects, resulting in a 35.32% increase in other income to CNY 6,301,913.15[12] - The company’s investment income rose by 42.79% to CNY 3,771,847.38, reflecting adjustments in financial product holdings[12] - Research and development expenses for the first nine months of 2023 were CNY 19.44 million, an increase of 5.86% from CNY 18.36 million in the same period of 2022[46] - The company’s financial expenses included interest expenses of CNY 1.63 million, which increased from CNY 0.93 million in the previous year[46] Accounts Receivable and Inventory - Accounts receivable increased by 33.62% to CNY 128,193,018.79, attributed to delayed payments from clients due to market conditions[12] - The company’s inventory stands at ¥33,830,706.15, down from ¥37,069,161.29 at the end of 2022, indicating a decrease of about 8.3%[34]